Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026

Summary by Carroll County Mirror-Democrat
PARIS, May 11, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

pharmatimes.compharmatimes.com

Pulsesight reports positive phase 1 data for PST‑611 in dry AMD

Early safety and efficacy signals support move into repeat‑dose phase 2a trial

Read Full Article
Carroll County Mirror-DemocratCarroll County Mirror-Democrat

Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026

PARIS, May 11, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company

·Mount Carroll, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Carroll County Mirror-Democrat broke the news in Mount Carroll, United States on Monday, May 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AMD icon

AMD

Paris, France icon

Paris, France

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal